Diabetes Research: Open Access
Masaki OKADA1, Hiroshi BANDO1,2,3*, Noboru IWATSUKI1, Kazuki SAKAMOTO1, Tomoya OGAWA1
1Sakamoto Hospital, Higashi Kagawa city, Kagawa, Japan
2Tokushima University / Medical Research, Tokushima, Japan
3Japan Low Carbohydrate Diet Promotion Association, Kyoto, Japan
Corresponding Author: Hiroshi BANDO, MD, PhD, FACP ORCID iD
Address: Tokushima University /Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan.
Received date: 06 May 2022; Accepted date: 28 May 2022; Published date: 06 June 2022
Citation: Okada M, Bando H, Iwatsuki N, Sakamoto K, Ogawa T. Effective Single Twymeeg Administration for Elderly Patient with Type 2 Diabetes (T2D), Arthralgia and Depression as Common Medical Problems. Diab Res Open Access. 2022 June 06;4(1):1-7.
Copyright © 2022 Okada M, Bando H, Iwatsuki N, Sakamoto K, Ogawa T. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: Imeglimin, Twymeeg, Duloxetine Hydrochloride, Cymbalta, Type 2 Diabetes, Depression, Mild Cognitive Impairment
Abbreviations: Twymeeg: Imeglimin; Cymbalta: Duloxetine Hydrochloride; T2D: Type 2 Diabetes; MCI: Mild Cognitive Impairment
Abstract
Background: Imeglimin (Twymeeg) has been effective for patients with type 2 diabetes (T2D).
Case Presentation: The patient is an 82-year-old female with T2D, arthralgia, and depression.
Results: She was given duloxetine hydrochloride (Cymbalta) and Twymeeg, leading to improved symptoms of low back pain (LBP), knee osteoarthritis, osteoporosis, depression, and possible mild cognitive impairment (MCI). HbA1c decreased from 8.8% to 7.1% for 4 months with a single administration of Twymeeg 2000mg/day.
Discussion: In recent clinical practice, elderly cases often tend to have simultaneously these problems, which are medical and social crucial problems. Twymeeg and Cymbalta may be indispensable agents for future practice.
